PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
2.990
-0.070 (-2.29%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. The company has research and development collaboration with ImmunoGenesis, Inc. to enhance cancer immunotherapy using PLEX technology.
PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid Ltd.
| Country | Israel |
| Founded | 2008 |
| IPO Date | Jun 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dikla Czaczkes Akselbrad |
Contact Details
Address: 18 Hasivim Street Petah Tikva, 4959376 Israel | |
| Phone | 972 7 4719 5700 |
| Website | polypid.com |
Stock Details
| Ticker Symbol | PYPD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001611842 |
| CUSIP Number | M8001Q118 |
| ISIN Number | IL0011326795 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs |
| Dikla Czaczkes Akselbrad | Chief Executive Officer and Director |
| Jonny Missulawin | Chief Financial Officer |
| Ori Warshavsky | Chief Operating Officer - US |
| Maria Rubin | Vice President of Operations |
| Tal Vilnai | General Counsel and Corporate Secretary |
| Rivi Lev-ari | Vice President of Human Resource |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | EFFECT | Notice of Effectiveness |
| Jan 21, 2025 | F-3 | Filing |
| Jan 17, 2025 | 6-K | Report of foreign issuer |
| Jan 2, 2025 | D | Notice of Exempt Offering of Securities |
| Dec 26, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |